GET DAILY SIGNALSPharvaris (PHVS): Following Progress on Oral Therapies for Hereditary Angioedema
Key Takeaways
- PHVS is the Nasdaq ticker for Pharvaris N.V., a late-stage clinical biopharmaceutical company developing oral therapies for rare diseases.
- The company's lead drug candidate, deucrictibant, targets hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition.
- Pharvaris is developing deucrictibant in two forms: an immediate-release capsule for on-demand treatment and an extended-release tablet for prevention (prophylaxis).
- The company is pre-revenue, meaning it has not yet generated product sales and currently funds operations primarily through equity financing.
- Investors follow PHVS for its pipeline progress, clinical trial results, and potential path toward regulatory approval and commercialization.
Company Overview
Pharvaris N.V. focuses on developing and eventually commercializing therapies for rare diseases that still lack effective options. Its initial emphasis is on angioedema and other bradykinin-mediated conditions, where excess bradykinin causes blood vessels to leak and produce swelling. The lead program centers on deucrictibant, an oral small-molecule bradykinin B2-receptor antagonist. Many analysts and clinicians see an effective oral treatment as a notable step forward because most current hereditary angioedema options rely on injections or infusions. PHVS trades on the Nasdaq Global Select Market.
Background and Development Pipeline
Pharvaris was founded in 2015 and is based in Leiden, the Netherlands. It went public on Nasdaq in February 2021. As a clinical-stage company, it directs most resources toward research and development without yet having a marketed product or product revenue. The strategy involves advancing deucrictibant through trials, securing approvals, and then bringing it to market. The molecule blocks the B2 receptor that bradykinin uses to trigger swelling in hereditary angioedema.
Two formulations are in development. The immediate-release capsule is designed for treating acute attacks as they happen, while the extended-release tablet aims at preventive use to lower attack frequency. The company has also looked at deucrictibant for related conditions such as acquired angioedema due to C1-inhibitor deficiency. It operates in the orphan-drug segment, where it competes with established injectable treatments and other emerging oral candidates.
When reviewing sector peers, I sometimes cross-check industry benchmarks with Tickeron’s AI Screener to see how clinical-stage names stack up on volatility and pipeline metrics.
What Attracts Investors to PHVS
Interest in PHVS tracks closely with clinical and regulatory updates on deucrictibant. Hereditary angioedema involves unpredictable swelling episodes that can affect limbs, the abdomen, face, or airway, and laryngeal attacks can be serious. An oral option could make treatment more accessible, potentially increasing how often patients address attacks and improving adherence to preventive regimens. The dual on-demand and prophylactic approach lets the program target two major parts of the HAE market from one platform. Orphan-drug incentives may also offer market exclusivity if approval is reached.
Financially, the profile matches most clinical-stage biotechs: ongoing operating losses and negative earnings per share while trials continue, supported by cash reserves. Primary catalysts for investors are therefore data readouts, regulatory filings, and financing or partnership news rather than revenue figures. One thing that stands out is how clinical milestones tend to drive the valuation more than traditional financial ratios at this stage.
Risks to Keep in Mind
Clinical-stage biotech investing carries real risk, and Pharvaris illustrates the point. With no approved products and no product revenue, value hinges largely on one lead asset. Failure to meet endpoints or regulatory delays could materially change the outlook. Regulatory hurdles such as additional data requests or clinical holds remain possible. Competition in the HAE space includes several established therapies and other oral programs, so pricing and reimbursement will matter even after approval. As a pre-revenue firm, additional equity raises could dilute shareholders. Biotech valuations often swing sharply on news flow and broader market sentiment, so position sizing and risk management deserve careful attention.
Using AI Tools for Biotech Research
When screening for ideas in the rare-disease space or comparing clinical-stage names, I find Tickeron’s AI Screener helpful for quickly filtering by technical indicators, fundamentals, volatility, trends, and AI-generated signals. The platform lets me set custom criteria across industries and price patterns, which can surface names that fit a particular strategy without manually reviewing thousands of securities. It serves as one practical step in my broader due-diligence process.
Conclusion
Pharvaris N.V. centers its value on deucrictibant, an oral candidate for hereditary angioedema. The combination of on-demand and prophylactic development plus oral convenience sets it apart in a field long dominated by injectables. At the same time, the pre-revenue position and single-asset focus highlight the meaningful risks typical of clinical-stage biotech. For investors, PHVS represents a high-risk, high-reward profile driven mainly by pipeline execution and regulatory outcomes rather than current financial results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PHVS in upward trend: price rose above 50-day moving average on November 06, 2026
PHVS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PHVS as a result. In 98 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PHVS just turned positive on October 20, 2026. Looking at past instances where PHVS's MACD turned positive, the stock continued to rise in 48 of 55 cases over the following month. The odds of a continued upward trend are 87%.
The 10-day moving average for PHVS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHVS advanced for three days, in 192 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
PHVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for PHVS moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 59 cases where PHVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for PHVS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.026) is normal, around the industry mean (3.498). P/E Ratio (-13.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. PHVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement